145results about How to "Inhibit biological activity" patented technology

Engineered antibodies to human IL-23pl9 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.

The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V_H, V_L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.

The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.

The invention provides a broad spectrum heavy metal activity deactivator preparation method. The present invention relates to a soil conditioning agent preparation method, which comprises the following steps: (A) taking humic acid-rich peat, digest compost or a forest soil humus layer, and carrying out screening to provide a spare use; (B) adding the humic acid-rich material to HCl or HNO3 to soak, and stirring 2-3 times; (C) filtering the soaked material with a bamboo drying pad, washing 2-3 times with clear water, and carrying out air drying to a moisture content of less than 5%; (D) sequentially adding ZnSO4.7H2O, sodium silicate and sodium selenite to the material obtained from the step (C), carrying out aging on the mixed material for 2-3 days and uniformly mixing; and (E) adding limestone powder to the material obtained from the step (D), and completely and uniformly mixing to prepare the broad spectrum heavy metal deactivator. With the combination inhibitor prepared by the preparation method, activities of soil heavy metals can be significantly inactivated, the heavy metals can be inhibited from entering the food chain, and risks on human health by the heavy metals can be reduced.

The invention relates to a 2-arylaminopyridine, pyrimidine or triazine derivative and a preparation method and application thereof. The 2-arylaminopyridines, pyrimidines or triazine derivatives may act on certain mutant forms of epidermal growth factor receptors such as L858R activating mutants, delE746_A750 mutants, Exonl9 deletion activating mutants and T790M drug resistant mutants , for use in the treatment and prevention of diseases and conditions. The 2-arylaminopyridine, pyrimidine or triazine derivatives are useful for the treatment and prevention of cancer. The present invention also relates to pharmaceutical compositions comprising 2-arylaminopyridines, pyrimidines or triazine derivatives, intermediates useful in the preparation of 2-arylaminopyridines, pyrimidines or triazine derivatives, and the use of 2-arylamino Pyridine, pyrimidine or triazine derivatives in the treatment of diseases mediated by various forms of EGFR.

The present invention provides methods and compositions for expressing eukaryotic membrane proteins.

Disclosed is a method and test kit to diagnose tumorigenicity or the presence of tumor cells in a patient by detecting the level of FBLN-3 expression or biological activity in the patient. Also disclosed are methods to identify regulators of tumor cell growth, motility and/or invasion, by identifying regulators of FBLN-3 expression or activity. Methods to identify anti-angiogenic and pro-angiogenic agents are also described, wherein such factors regulate the expression and/or activity of FBLN-3. Finally, the present invention relates to therapeutic methods and reagents for the inhibition of tumor growth and development and/or for the inhibition or promotion of angiogenesis, using FBLN-3, homologues and analogs thereof, and agents that modulate the expression and/or activity of FBLN-3.

The present invention relates to compositions and methods for cancer diagnosis, treatment and research, including but not limited to, cancer markers and uses of cancer markers. In particular, the present invention provides compositions and methods for targeting MCP-1 in prostate cancer.

The invention discloses organic titanium-potassium fertilizer and a preparation method thereof. The fertilizer is characterized in that the fertilizer takes water as solvent; and the compositions of the fertilizer in every liter of water are: 5 to 100g of organic chelated titanium, 75 to 200g of glucose, 600 to 800g of potassium citrate, 0 to 130g of borax or boric acid, 0 to 90g of humic acid or potassium humate, 0 to 60g of EDDHA chelating agent and 7 to 12g of auxiliary agent. The organic titanium-potassium fertilizer not only makes effective use of the prior fertilizer resources to change the status quo of constant high potassium fertilizer price in China, relieve contradictions between supply and demand and save resource, but also overcomes the differences between southern China and northern China in climate, soil, and the like, thereby playing a remarkable role in solving soil hardening, salinization and acidification. The fertilizer can also improve adverse circumstance resistance of crops, and is suitable for soil of various climates and various crops; moreover, the fertilizer better ensures yield increase of various crops and solves the problems of farmers such as low economic benefits, income increase, labor intensity reduction and the like; meanwhile, the fertilizer is propitious to advocate rational application of the fertilizer and improve the quality of farm products.

Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.

The invention relates to the field of organic synthesis and medicine, and discloses a preparation method for N-substituted methyl-3,5-disubstituted benzylidene base-4-piperidone and biological activity for efficiently inhibiting cell line proliferation such as leukemia, ovarian cancer, breast cancer, liver cancer and esophagus cancer. The method includes: starting from various substituted methylamine and methyl acrylate, sequentially going through Michael addition, Dieckmann condensation, acidolysis and decarboxylation to obtain N-substituted methyl-4-piperidone, and subjecting the N-substituted methyl-4-piperidone to aldol reaction with substituted benzaldehyde to obtain a target compound N-substituted methyl-3,5-disubstituted benzylidene base-4-piperidone. The target compound can selectively and efficiently inhibit cell line proliferation such as leukemia, ovarian cancer, breast cancer, liver cancer and esophagus cancer, and activity of inhibiting carcinoma cell line proliferation is obviously higher than conventional chemotherapeutic 5-fluorouracil.

The present invention discloses a coronary artery medicine coating scaffold for inhibiting endometrial hyperplasia and preventing restenosis in the scaffold. It includes dilating scaffold base body and inner coating layer coated on the dilating scaffold base body, the above-mentioned inner coating layer is formed from medicine carrier and ligustrazine, their mass ratio is 3:1-1:3, the above-mentioned inner coating layer is one of methyl acrylate, methyl methacrylate copolymer, polylactic acid, polyglycollic acid, polymonoracemic lactic acid, polylactide-diglycolide polymer, phosphorylcholine, ethyl polyurethane inorganic micropore aluminium oxide and cellulose or their composite.

The invention provides a class of 4-halogenated methyl-1,2,3-thiadiazole compounds and a preparation method and application thereof, relating to heterocyclic compounds containing 1,2,3-thiadiazole, which have the following chemical general formula as shown in the specification of the invention. The invention discloses the general formula, the synthesis method of the compounds, application of the compounds used as insecticides, disinfectants, antiphytoviral agents and plant activators and the process for preparing insecticides, disinfectants, antiphytoviral agents and plant activators by mixing the compounds with agriculturally acceptable additives or synergists; the invention also discloses the application of combining the compounds with commercial insecticides, disinfectants, antiphytoviral agents and plant activators to prevent and treat diseases, pests, virus diseases in agriculture, forestry and horticulture, and the preparation method of the compounds.

The invention provides a 5-halogenated methyl-1,2,3-thiadiazole derivative and a preparation method and use thereof. The invention relates to heterocyclic compounds containing the 1,2,3-thiadiazole which have a chemical structure general formula shown in the specifications. The invention discloses the general formula and a synthesis method of the compounds, the use of the compounds as pesticide, bactericide, plant virus resisting agent and plant activator, and the process for preparing the pesticide, the bactericide, the plant virus resisting agent and the plant activator by mixing the compounds and an agriculturally acceptable assistant or synergist. The invention further discloses the use of the compounds in preventing and controlling the agricultural, forest and garden diseases, insect damages and virus diseases by combining the compounds with the commodity pesticide, the bactericide, the plant virus resisting agent and the plant activator, and the preparation method.

Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides).

The present invention relates to nuclear factor-K Bp50 subunit conjugated peptide, its preparation and application, in more concrete, it is a small polypeptide which can be specifically conjugated with nuclear factor-k Bp50 subunit and can be used for inhibiting its activity. Its amino acid sequence can be referred to sequence table.

The invention provides a humanized anti-human interferon (IFN) alpha antibody, as well as a coding gene and an application thereof. By combining and applying gene engineering means and phage surface display technology, a plurality of subtype anti-human IFN alpha gene engineering single chain antibodies are screened from a fully synthetic single chain human antibody library, and a gene sequence of a variable region of the antibodies is obtained, holistic monoclonal Fab and IgG antibody recombinant carrier are constructed on that basis, and a high-purity antibody molecule is obtained by expression and purification of mammalian cells. The affinity of combination of the obtained antibody Fab and human IFN alpha-2 is not more than 0.5nM, and the affinity of combination of the obtained antibody Fab and IFN alpha-2 is not more than 5nM. The antibody can be used for effectively blocking the biological activity of IFN alpha-2 and other multiple subtype IFN alpha at a cellular level. The humanized anti-human IFN alpha antibody provides a specific antibody medicine for treatment of IFN related diseases, such as systemic lupus erythematosus and other autoimmunity diseases.

The invention discloses a pig compound feed production method through recycling of poultry excrement. The technology is high in recycling utilization degree, easy to realize large-scale industrialized production, facilitates recycling utilization of waste produced during poultry cultivation and solves two difficulties of environment contamination and shortage of pig feeding resource in the conventional poultry cultivation. According to the method, under the compound action of secondary fermentation of microorganisms, and cellulase, the fermentation wine mashes are added during fermentation and the poultry excrement is converted to the pig compound feed with high protein content, bright color and nice flavor; the pig compound feed is better in deodorization effect, and high in nutritional value; through the adoption of the multi-strain anerobic fermentation, the biological activity of the pathogenic microorganisms is restrained and the pathogenic microorganisms can be effectively restrained and killed by lactic acid generated by lactic acid bacteria, antibiotic matters generated by actinomycetes and antioxidant matters generated by other beneficial microorganisms, so that the pig compound feed is harmless and the feed products meet the feed hygienic standard; in addition, the method is simple in process and is easy to realize large-scale industrialized production.

The invention relates to polypeptide with an anti-tumor effect and a preparation method and application of the polypeptide. The anti-tumor polypeptide is composed of 21 amino acids, and the amino acid sequence is shown in SEQ ID No.1. The polypeptide is synthesized through a solid phase chemical synthesis method, the yield is high, the process is stable, and the molecular weight is 2265.15Da. The polypeptide has activity for restraining tumor cell proliferation, invasion and metastasis, is safe and effective for treating tumors and has important application value on clinical anti-tumor therapies.

The invention discloses an oxygen-containing five-membered heterocyclic compound, a synthesis method, a pharmaceutical composition and application thereof, and belongs to the technical field of medicines and preparation and application thereof. The oxygen-containing five-membered heterocycle has the biological activity of inhibiting the protein tyrosine phosphatase SHP2, can be used as a tool compound for researching the biological function relevance of the protein tyrosine phosphatase SHP2 in the cell signal transduction process, and provides a new means for preventing and treating cancers and metabolic and immune diseases.

The present invention is directed to compositions and methods of screening apoproteins for the elucidation of modulators of metalation of apoproteins.

The invention relates to a cosmetic composition with whitening and skin brightening functions. The cosmetic composition contains effective quantity of nicotinamide, ascorbyl glucoside, hydrolyzed glucosamine, kakadu plum extracts and yeast extracts, and is prepared from the following ingredients in percentage by mass: 1 to 4 percent of nicotinamide, 0.1 to 1 percent of ascorbyl glucoside, 0.01 to0.5 percent of hydrolyzed glucosamine, 0.1 to 2 percent of kakadu plum extracts, 0.1 to 10 percent of yeast extracts and 82.5 to 98.69 percent of cosmetics substrates. The yeast extracts selected by the cosmetics composition contain amino acid, peptides, nucleotide, vitamin and the like; the amino acid is favorable for collagen synthesis; the nucleotide can promote metabolism and improve the protein synthesis speed; the skin free radical resistant capability and the like are improved.

The invention provides the antibody 2C3 and target binding members based on 2C3 which binds interleukin-25. These are useful in therapy, e.g. the treatment of asthma.

Anti-S100A4 antibody molecules that are capable of inhibiting the biological activity of S100A4 in promoting tumour progression and/or in inducing tumour metastasis are described. The antibody molecules are also useful in the treatment of inflammatory conditions. The properties of the antibodies are demonstrated using in vitro and in vivo assays.

The invention discloses a 2(5H)-furan-2-one derivative as shown in a formula I which is described in the specification. R is substituted or unsubstituted phenyl, or substituted or unsubstituted naphthyl as shown in a formula. The invention also discloses a preparation method of the 2(5H)-furan-2-one derivative. ROH and 5-bromo-furan-2 (5H)-one are used as raw materials, water and an organic solvent are used as reaction solvents, and a target compound is obtained through a reaction in the presence of an inorganic base and a phase transfer catalyst. The 2(5H)-furan-2-one derivative has the effect of inhibiting rice tillering, compared with strigolactones GR24, the 2(5H)-furan-2-one derivative is simple in structure and low in preparation price, the cost is less than one ten thousandth of thecommercialized price of GR24, and the 2(5H)-furan-2-one derivative has potential commercialized prospects.